Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-1084 in Participants With Hepatic Impairment
NCT07219550Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calderasib in cancer, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve from 0 to the Time of the Last Quantifiable Sample at 7 days, Area Under the Concentration Versus Time Curve from 0 to Infinity at 7 days and 6 more. Started Nov 2025; status: completed.
02
Drugs
calderasib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07219550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219550.